Author archive for admin.adstream

  • aside

    Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,…

    by
  • aside

    ISOFOLS BOKSLUTSKOMMUNIKÉ JANUARI – DECEMBER 2016

    Read more here –>

    by
  • aside

    Isofol Medical has successfully advanced to the next dose level of Modufolin® in a phase I/II clinical trial in colorectal cancer.

    Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or…

    by
  • aside

    Isofol announces successful meetings with European and US regulatory authorities regarding the design of a pivotal Phase II clinical trial of Isofol’s lead Drug candidate, Modufolin®

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology is pleased with the…

    by
  • aside

    Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment…

    by
  • aside

    Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

    Isofol Medical AB today announced that the first dose cohort with Modufolin® as rescue therapy, after treatment with two cycles…

    by
  • aside

    Patent covering the use and pharmaceutical composition of Isofol’s lead Drug candidate, Modufolin®, allowed by United States Patent and Trademark Office

    Isofol Medical AB today announced that the United States Patent and Trademark Office has allowed Isofol’s patent No. 12/805,287, covering…

    by
  • aside

    First patient successfully treated with Modufolin® as a rescue therapy with high dose methotrexate (HDMTX) treatment in Osteosarcoma.

    Isofol Medical AB today announced that the first patient treated with Modufolin®, as rescue therapy, after treatment with two cycles…

    by
  • Stockholm Corporate Finance Life Science Day 2015

    Isofol’s Chief Scientific Officer, Anders Vedin presented at the Stockholm Corporate Finance Life Science Day 2015 at Operaterrassen in Stockholm.…

    by
  • aside

    Isofol Appoints the Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemotherapy Asset

    Gothenburg, Sweden, Cambridge UK, and Clinton NJ – February 2015 – Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in…

    by